Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in advanced melanoma with BRAF V600 mutation
NCT05114603Phase 2Unknown
- Sponsor
- Henlius
- Start
- Mar 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HLX208 in melanoma (2 arms), sponsored by Henlius. Primary endpoint: Objective Response Rate up to 6 months. Status: unknown.
02
Drugs
HLX208
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05114603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114603.